You are here

Justice News

Department of Justice
U.S. Attorney’s Office
District of Maryland

Thursday, January 25, 2018

Nevada Man Indicted For Distribution Of Anabolic Steroids And Drug Misbranding


FOR IMMEDIATE RELEASE                                                      Contact ELIZABETH MORSE                                                                 at (410) 209-4885



Greenbelt, Maryland – A federal grand jury has indicted George Sambuca a/k/a “Jack Yates,” a/k/a “Steven Thompson,” age 32, of Henderson, Nevada, today on charges related to a scheme to defraud customers by mislabeling drugs and distributing anabolic steroids. The indictment was returned on November 15, 2017, and unsealed upon the arrest of the Sambuca.


The indictment was announced by Acting United States Attorney for the District of Maryland Stephen M. Schenning; and Special Agent in Charge Mark S. McCormack of the Food and Drug Administration - Office of Criminal Investigations, Metro Washington Field Office.


According to the four-count indictment, Sambuca distributed the anabolic steroids, Testosterone, Nandrolone, Stanozolol, Oxandrolone, and Oxymetholone, all of which are Schedule III controlled substances. Sambuca mislabeled these drugs as “TEST SUSTANON 350MG,” “DBOL 5g” and “SUSTANON 350MG/ML . . . 100cc” and sent them from his residence in Nevada to Maryland on two separate occasions, conducting his business under the name of “Dynasty Labs.”


Sambuca faces a maximum of 10 years imprisonment for each of the two counts of Distribution of Anabolic Steroids and a maximum of 3 years imprisonment for each of the two counts of Introduction of Misbranded Drugs into Interstate Commerce with Intent to Defraud and Mislead.  Sambuca had an initial appearance on January 19, 2018, in U.S. District Court for the Eastern District of Pennsylvania, where he was arrested and ordered detained. An initial appearance has not yet been scheduled in Greenbelt, Maryland.


An indictment is not a finding of guilt.  An individual charged by indictment is presumed innocent unless and until proven guilty at some later criminal proceedings. 


Acting United States Attorney Stephen M. Schenning commended the FBI and the FDA-OCI for their work in the investigation.  Mr. Schenning thanked Assistant U.S. Attorney Kelly Hayes who is prosecuting the case.


Updated January 25, 2018